Forbes spotlights 30 healthcare innovators under 30

Amy Baxter | | Health Exec | Management

Forbes released its annual 30 under 30 list, spotlighting entrepreneurs, leaders and stars across 20 different industries, including healthcare.

Those on the healthcare list include capitalists investing in therapeutics, researchers looking for ways to improve diagnostic tests through CRISPR technology and entrepreneurs seeking to diagnose symptoms through telehealth.

Others are looking at stem cell therapies, cancer detection, easing the bottleneck of experimental drug testing and how to equip Africa with digital technology in healthcare.

The seventh Forbes 30 under 30 list featured 600 individuals. Nominations were vetted by a panel of judges and reporters.

See the full healthcare list below:

The 2019 30 Under 30

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.